var title_f6_51_6960="Right hepatic radoca bile leak";
var content_f6_51_6960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right hepatic radical bile leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP shows extravasation of contrast from a right hepatic bile duct radical (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6960=[""].join("\n");
var outline_f6_51_6960=null;
var title_f6_51_6961="LV normal cardiomyopathy";
var content_f6_51_6961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricle in cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A four chamber view from the two dimensional echocardiogram of a normal heart is shown in the panel A. In panel B, the echocardiogram from a patient with cardiomyopathy is shown and diagrammed. Note the cardiomyopathy heart is more spherical than its normal counterpart; the developing of a spherical configuration is fairly typical of cardiomyopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6961=[""].join("\n");
var outline_f6_51_6961=null;
var title_f6_51_6962="Patient information: Stitches (The Basics)";
var content_f6_51_6962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16586\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/43/11955\">",
"         Stitches",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/10/42145\">",
"         Patient information: Taking care of bruises (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43185\">",
"         Patient information: Taking care of cuts and scrapes (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Stitches (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/stitches-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7433760\">",
"      <span class=\"h1\">",
"       What are stitches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Stitches are a way doctors can close certain types of cuts. A doctor uses a special needle and thread to put in stitches. He or she sews the edges of the cut together and ties knots to hold the stitches in place (",
"      <a class=\"graphic graphic_figure graphicRef74759 \" href=\"UTD.htm?11/43/11955\">",
"       figure 1",
"      </a>",
"      ). The term doctors use for stitches is &ldquo;sutures.&rdquo;",
"     </p>",
"     <p>",
"      There are 2 main types of stitches:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Absorbable &ndash; These stitches dissolve over time. They do not need to be taken out.",
"       </li>",
"       <li>",
"        Nonabsorbable &ndash; These stitches need to be taken out after a certain amount of time. They do not dissolve.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another way doctors can close cuts is with staples. Staples that go in the body are different from those used on paper. To put staples in, doctors use a special stapler. Staples need to be taken out after a certain amount of time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433775\">",
"      <span class=\"h1\">",
"       How do I know if I need stitches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will need stitches if your cut is wide, jagged, or goes all the way through your skin. A cut will heal on its own without stitches, but stitches help a cut heal faster and leave less of a scar.",
"     </p>",
"     <p>",
"      Minor cuts and scrapes that do not go all the way through the skin do not need stitches. If you get a cut and don&rsquo;t know if you need stitches, check with your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433790\">",
"      <span class=\"h1\">",
"       What happens when I get stitches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before the doctor stitches your cut, he or she will clean out the cut well. He or she will also give you numbing medicine so that you don&rsquo;t feel pain when the stitches go in.",
"     </p>",
"     <p>",
"      After the doctor stitches your cut, he or she will cover the area with gauze or a bandage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433805\">",
"      <span class=\"h1\">",
"       Why is it important to take care of my stitches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to take care of your stitches so that your cut heals well and doesn&rsquo;t get infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433820\">",
"      <span class=\"h1\">",
"       How do I take care of my stitches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will give you specific instructions, depending on the type of stitches you have and where they are.",
"     </p>",
"     <p>",
"      Here is some general advice you can follow:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keep your stitches dry and covered with a bandage. Nonabsorbable stitches need to be kept dry for 1 to 2 days. Absorbable stitches need to be kept dry longer. Your doctor or nurse will tell you exactly how long to keep your stitches dry.",
"       </li>",
"       <li>",
"        Once you no longer need to keep your stitches dry, gently wash them with soap and water whenever you take a shower. Do not put your stitches underwater, such as in a bath, pool, or lake. Getting your stitches too wet can slow down healing and raise your chance of getting an infection.",
"       </li>",
"       <li>",
"        After you wash your stitches, pat them dry and put an antibiotic ointment on them.",
"       </li>",
"       <li>",
"        Cover your stitches with a bandage or gauze, unless your doctor or nurse tells you not to.",
"       </li>",
"       <li>",
"        Avoid any activities or sports that could hurt the area of your stitches for 1 to 2 weeks. (Your doctor or nurse will tell you exactly how long to avoid these activities.) If you hurt the same part of your body again, your stitches can break, and the cut can open up again.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433835\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your stitches break or the cut opens up again.",
"       </li>",
"       <li>",
"        You get a fever.",
"       </li>",
"       <li>",
"        You have redness or swelling around the cut, or pus drains from the cut. It is normal for clear yellow fluid to drain from the cut in the first few days.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433849\">",
"      <span class=\"h1\">",
"       When will my stitches be taken out?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor who puts in the stitches will tell you when to see your doctor or nurse to have your stitches taken out. Nonabsorbable stitches usually stay in for 5 to 14 days, depending on where they are.",
"     </p>",
"     <p>",
"      Staples need to be taken out with a special staple remover. But doctors&rsquo; offices don&rsquo;t always have this device. Ask the doctor who puts in your staples for a staple remover. Then bring it to your doctor&rsquo;s office when you have your staples taken out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433864\">",
"      <span class=\"h1\">",
"       What should I do after my stitches are out?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After your stitches are out, you should protect the scar from the sun. Use sunscreen on the area or wear clothes or a hat that covers the scar.",
"     </p>",
"     <p>",
"      Your doctor or nurse might also recommend that you use certain lotions or creams to help your scar heal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7433879\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=see_link\">",
"       Patient information: Taking care of cuts and scrapes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=see_link\">",
"       Patient information: Taking care of bruises (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/51/6962?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16586 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6962=[""].join("\n");
var outline_f6_51_6962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433760\">",
"      What are stitches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433775\">",
"      How do I know if I need stitches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433790\">",
"      What happens when I get stitches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433805\">",
"      Why is it important to take care of my stitches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433820\">",
"      How do I take care of my stitches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433835\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433849\">",
"      When will my stitches be taken out?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433864\">",
"      What should I do after my stitches are out?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7433879\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/43/11955\">",
"      Stitches",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=related_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=related_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_51_6963="Pustular psoriasis 1";
var content_f6_51_6963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustular psoriasis 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 28-year-old woman developed fever, hypotension, leukocytosis, widespread erythema, and pustules at 34 weeks gestation during her first pregnancy. She was hospitalized for several months, and the eruption resolved within the first month after delivery of a normal full term infant. A skin biopsy showed changes typical of pustular psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6963=[""].join("\n");
var outline_f6_51_6963=null;
var title_f6_51_6964="ECHO total anomalous pulmonary venous connection";
var content_f6_51_6964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1098px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76860/tapvrech_conv.mp4?title=ECHO+total+anomalous+pulmonary+venous+connection\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Echocardiogram of cardiac total anomalous pulmonary venous connection to a dilated coronary sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Brian Soriano.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6964=[""].join("\n");
var outline_f6_51_6964=null;
var title_f6_51_6965="Zaleplon: Patient drug information";
var content_f6_51_6965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zaleplon: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"     see \"Zaleplon: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sonata&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zaleplon or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696906",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug unless you can get at least 4 hours of sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you wake up in the early morning, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take naps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak. This drug works fast so take when already in bed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take when you have trouble falling asleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid taking this drug with high-fat meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug only for short periods of time (7 to 10 days).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11150 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-D6EAFC90AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6965=[""].join("\n");
var outline_f6_51_6965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235597\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019199\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019201\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019200\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019205\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019206\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019208\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019203\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019204\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019209\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019210\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=related_link\">",
"      Zaleplon: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_51_6966="Radial head and olecranon ossification";
var content_f6_51_6966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radial head and olecranon ossification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Limits of the border of olecranon ossification at birth, 8 years, and 12 years.",
"    <br>",
"     (B) Lateral view of elbow at age 6 months. The radial head is not visible and the proximal margin of the olecranon is perpindicular to the long axis of the ulna.",
"     <br>",
"      (C) Lateral view of the elbow at age 6 years. A small oval nucleus marks the initial ossification of the radial head. The proximal margin of the olecranon is now oblique to the long axis of the ulna.",
"      <br>",
"       (D) At 10 years of age, the radial head is now widened and flat and a secondary ossification center for the olecranon is forming along with a sclerotic border at the proximal olecranon metaphysis.",
"       <br>",
"        (E) Bipartite secondary ossification center of the olecranon. The larger center is the traction center (black arrow). The smaller, more proximal center is the articular center (white arrow).",
"        <br>",
"         (F) Before complete fusion of the radial head and olecranon, a partial line remains (arrows), bordered by a sclerotic margin.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"         </div>",
"         <div class=\"contractual\">",
"          <br/>",
"          <a href=\"file://www.lww.com\">",
"           file://www.lww.com",
"          </a>",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6966=[""].join("\n");
var outline_f6_51_6966=null;
var title_f6_51_6967="Cong rubella retinopathy";
var content_f6_51_6967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital rubella retinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Salt and pepper\" retinopathy of congenital rubella syndrome. Color fundus photograph (A). Fluorescein angiogram (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold, DH, Weingeist, TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6967=[""].join("\n");
var outline_f6_51_6967=null;
var title_f6_51_6968="Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)";
var content_f6_51_6968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/51/6968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6968/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/51/6968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6968/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/51/6968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6968/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/51/6968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Zollinger-Ellison syndrome (ZES) have gastrin-secreting tumors and the associated clinical consequences. This disorder can occur sporadically, or as a manifestation of multiple endocrine neoplasia type 1 (MEN 1). Medical therapy is the current standard of care for most patients with ZES as part of the MEN 1 syndrome. By contrast, many patients with sporadic ZES are candidates for surgical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prior to the development of effective acid suppression therapy, the major morbidity and mortality of ZES were related to complications of fulminant peptic ulcer disease; total gastrectomy was the only effective measure to protect patients from these problems [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of H2 antagonists and the more powerful",
"    <span class=\"nowrap\">",
"     hydrogen/potassium",
"    </span>",
"    ATPase (proton pump) inhibitors has resulted in a significant decrease in morbidity and mortality from ulcer disease and has obviated the need for gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/2\">",
"     2",
"    </a>",
"    ]. Of 212 patients with ZES studied prospectively for a mean of 13.8 years, a ZES-related cause of death could be identified in only half of the 31 percent who died. All of the ZES-related deaths were due to tumor spread; none were due to hypersecretory complications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the two current goals of therapy in ZES [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Control of the complications resulting from autonomous release of gastrin",
"     </li>",
"     <li>",
"      Control of the tumor itself",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of medical management in Zollinger-Ellison syndrome (ZES) is to limit the clinical manifestations and complications of peptic ulcer disease. Because peptic symptoms in patients with ZES are often a poor marker of acid secretion, formal acid secretory studies have been advocated to guide the dosage of acid suppressants, with the goal of reducing gastric acid secretion to below 10",
"    <span class=\"nowrap\">",
"     mEq/h",
"    </span>",
"    prior to the next dose [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/5\">",
"     5",
"    </a>",
"    ]. However, such studies are often not available even in major medical centers, and it has become customary among many gastroenterologists to initiate and maintain proton pump inhibitors at high dosage (eg, 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ), using symptoms alone as a signal to increase the dose. To the author's knowledge, there have been few if any episodes of major peptic diathesis associated with this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proton pump inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"     dexlansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    ) effectively block acid secretion by irreversibly binding to and inhibiting the",
"    <span class=\"nowrap\">",
"     hydrogen/potassium",
"    </span>",
"    ATPase that resides on the luminal surface of the parietal cell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .) Their effects last for more than 24 hours; as a result, many patients can be treated with a once a day regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/5\">",
"     5",
"    </a>",
"    ]. A four-year prospective study of 40 patients with ZES who were treated with omeprazole found the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      effectively controlled acid output in all patients",
"     </li>",
"     <li>",
"      Thirty-one patients could be managed by administration of the drug once a day, while nine patients required a 60 mg twice a day regimen",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      was able to completely resolve peptic symptoms in 23 of 29 patients who described symptoms while on H2 blocker therapy",
"     </li>",
"     <li>",
"      No patients experienced tachyphylaxis, and no hematologic, metabolic, or gastric toxicity was noted",
"     </li>",
"     <li>",
"      Endoscopy with gastric biopsy revealed no evidence of gastric carcinoid tumors as a complication of long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with ZES should be started on a high dose of a PPI (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    60 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    120 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    45 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    60 mg daily, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    120 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ]. The recommended dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"     dexlansoprazole",
"    </a>",
"    has not been established. Some patients require an early upward titration of these doses; however, once control of acid output has been achieved, a gradual dose reduction is usually possible. In a study of 37 patients who had received high dose omeprazole for almost two years, nearly 50 percent were able to titrate the maintenance dose down to 20 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/9\">",
"     9",
"    </a>",
"    ]. Overall, 95 percent of patients without MEN 1, severe gastroesophageal reflux, or previous partial gastrectomy had safe reductions in their medication dose. Intravenous formulations can be used in patients who cannot take oral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PPIs have been generally safe, even when used in high doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974871#H59974871\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While PPIs are able to control gastric acid secretion, somatostatin analogs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    can inhibit secretion of gastrin. However, due to the unpredictability of the response, they are not first-line agents for symptomatic patients with hypergastrinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a sporadic gastrinoma who do not have evidence of metastatic spread of disease should be offered exploratory laparotomy and resection with curative intent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/1,4,11\">",
"     1,4,11",
"    </a>",
"    ]. This recommendation is derived from the observation that in addition to eliminating or at least decreasing the need for antisecretory medical therapy, successful resection of sporadic gastrinomas protects against the possibility of eventual morbidity and death from metastatic spread of the tumor (see below). In the hands of an experienced surgeon, up to 50 percent of these patients will be cured [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood for surgical cure is especially high for extrapancreatic gastrinomas (eg, those in the duodenum or peripancreatic lymph nodes). In contrast, laparotomy is not routinely recommended for patients with Zollinger-Ellison syndrome (ZES) as part of MEN 1 since the multifocal nature of the tumors in this disorder almost uniformly precludes cure of gastrin hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eighty percent of curable gastrinomas lie within the gastrinoma triangle comprised of the head of the pancreas and the duodenal sweep. The combination of preoperative localization techniques makes it possible for the experienced surgeon to identify over 90 percent of sporadic gastrinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. Intraoperative transduodenal illumination and duodenotomy are of particular value in detecting very small gastrinomas arising in the wall of the duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .) In the unlikely event that a sporadic gastrinoma cannot be identified at surgery, we suggest deferring a Whipple's procedure in favor of closure, with the intent of serial imaging every six months to try to localize the neoplasm.",
"   </p>",
"   <p>",
"    Gastric secretion may not return to the normal range following gastrinoma resection because of a residual excess of gastric parietal cells, a consequence of the trophic effect of chronically elevated gastrin levels. Up to 40 percent of patients will require prolonged antisecretory therapy to control hyperacidity following curative resection, and such patients need continued monitoring for acid hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Of 50 patients who underwent curative resection for ZES, gastric hypersecretion was observed for a mean of eight years in 62 percent of patients and was judged to be extreme in 28 percent despite normal blood gastrin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A parietal cell (proximal gastric) vagotomy performed at the time of tumor resection has been advocated to reduce (and in some cases obviate) the need for postoperative medical therapy, particularly when complete resection of the gastrinoma tissue cannot be accomplished [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. However, it is currently uncommonly performed because of the efficacy of proton pump inhibitors. Furthermore, relatively few surgeons currently perform this procedure.",
"   </p>",
"   <p>",
"    The reduction in mortality associated with surgical therapy for patients without metastatic disease was illustrated in a prospective study of 124 patients with gastrinoma presumed to be free of metastasis by imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/20\">",
"     20",
"    </a>",
"    ]. Only 3 percent of the 98 patients who underwent resection developed liver metastases during a mean follow-up period of 6.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/20\">",
"     20",
"    </a>",
"    ]. By contrast, 23 percent of 26 patients treated medically developed metastatic disease over a slightly longer follow-up period (8.7 years). Two deaths due to metastatic gastrinoma occurred in the medically treated group compared with no disease-specific deaths in the operative group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reoperation for recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although surgery decreases the incidence of hepatic metastases and improves survival, long-term biochemical cure is achieved in less than 30 percent. Reoperation may be of benefit in those with recurrent ZES in whom the tumor can be identified and localized. In one study, for example, 17 patients with recurrent disease that was unequivocally imaged underwent 18 reoperations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/21\">",
"     21",
"    </a>",
"    ]. Five patients were disease free after operation, with a median follow-up of 28 months. There were no deaths in the cured group; two patients in the group with persistent disease died during a median follow-up of 34 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY FOR NONSURGICAL CANDIDATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with external beam radiotherapy (RT) in the management of islet cell tumors is limited. Although pancreatic neuroendocrine carcinomas were previously considered to represent a radioresistant tumor, data from published case reports and small case series suggest that RT can produce high rates of symptomatic palliation and freedom from local progression in patients who are not candidates for surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THERAPY OF METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the major metastatic site for gastrinomas, as it is with other islet cell tumors. The second most common site is bone (7 percent of patients in one series), almost all of which occur in patients who also have liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/27\">",
"     27",
"    </a>",
"    ]. The axial skeleton (spine or sacrum) is the primary site of bone metastasis, but other sites can be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/27\">",
"     27",
"    </a>",
"    ]. Somatostatin receptor scintigraphy and MRI are the best tests to detect these lesions; the former is preferred because extra-axial lesions can occur.",
"   </p>",
"   <p>",
"    Metastatic gastrinoma is now the most common cause of morbidity and mortality in patients with Zollinger-Ellison syndrome (ZES). Unfortunately, current treatment modalities are of limited benefit. A general algorithmic approach to therapy for patients with metastatic disease is outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef79461 \" href=\"UTD.htm?31/57/32671\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    is highly effective in controlling the symptoms associated with hormone hypersecretion in other pancreatic islet cell tumors that express somatostatin receptors such as glucagonomas and VIPomas, as well as carcinoid tumors; its efficacy is less predictable for gastrinomas. Nevertheless, octreotide can reduce gastrin levels, and may slow tumor growth; objective evidence of antitumor activity is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. As an example, in a report of 15 patients treated with octreotide for malignant gastrinoma and progressive hepatic metastases, seven had stabilization of tumor growth, and one an objective decrease in tumor size [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/30\">",
"     30",
"    </a>",
"    ]. The median duration of benefit was 25 months.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     Lanreotide",
"    </a>",
"    , another somatostatin analog, which is available internationally but not in the United States, appears to have similar clinical efficacy as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and is also available in a long-acting depot form (Lanreotide-SR) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Liver-directed therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic resection is indicated for the treatment of metastatic liver disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases (eg, pulmonary, peritoneal). Although the majority of cases will not be cured by surgery, prolonged survival is often possible, given the slow-growing nature of these tumors.",
"   </p>",
"   <p>",
"    In general, resection should be considered only for patients with a limited number of hepatic metastases and is most successful when undertaken with curative intent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hepatic artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver metastases derive most of their blood supply from the hepatic artery, whereas healthy hepatocytes derive about 70 percent of their blood supply from the portal vein. This provides the rationale for therapeutic embolization of the hepatic artery, with the goal of inducing necrosis of the metastases with minimal damage to normal liver parenchyma.",
"   </p>",
"   <p>",
"    Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is frequently applied as a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     RFA and cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches to the treatment of hepatic-predominant disease include radiofrequency ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/33\">",
"     33",
"    </a>",
"    ]. These procedures, which can be performed using percutaneous or laparoscopic approaches, appear to be less morbid than either hepatic resection or hepatic artery embolization. However, both techniques are applicable only to smaller lesions, and their long-term efficacy is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691456#H691456\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'RFA and cryoablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients with liver-isolated metastatic disease in whom orthotopic liver transplantation (OLT) has been attempted is small, and follow-up data are insufficient to judge whether complete cure has truly been achieved. The limited availability of donor organs in many regions has restricted investigation of this procedure.",
"   </p>",
"   <p>",
"    Until more data become available, most clinicians consider that liver transplantation is an investigational approach for metastatic islet cell tumors, including gastrinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691420#H691420\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotherapy and novel treatment approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with systemic chemotherapy for metastatic gastrinoma is limited. The traditional regimen of choice has been",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Although objective response rates as high as 69 percent were initially reported for metastatic islet cell tumors, with decreases in endocrine hyperfunction, the true radiologic response rate is probably between 10 and 40 percent. Uncertainty as to efficacy, as well as the toxicity of this regimen, which can include nausea, prolonged myelosuppression, and renal failure, has prevented its widespread acceptance as a standard first-line therapy for patients with metastatic islet cell tumors, including gastrinoma.",
"   </p>",
"   <p>",
"    Antitumor activity has also been shown for regimens containing the orally active alkylating agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . In the absence of comparative trials, the choice of first-line",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"      streptozocin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"    </span>",
"    or a temozolomide-based regimen must be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948956#H190948956\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Cytotoxic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest efficacy of conventional cytotoxic chemotherapy has prompted the development of novel therapeutic approaches for patients with advanced islet cell tumors. These include molecularly targeted therapy with inhibitors of the mammalian target of rapamycin (mTOR), small molecule tyrosine kinase inhibitors, and peptide receptor radioligand therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949026#H190949026\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Molecularly targeted therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949119#H190949119\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Peptide receptor radioligand therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality from gastrinomas largely depends upon whether the tumor is benign or malignant, and the extent of disease involvement. In an illustrative series, 185 patients with Zollinger-Ellison syndrome (ZES) were followed prospectively for a mean of 12.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/36\">",
"     36",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver metastases were found in 24 percent of patients at the time of diagnosis; the majority of these patients had a primary pancreatic neoplasm, and 67 percent had primary tumors that were greater than 3 cm in size",
"     </li>",
"     <li>",
"      Patients with liver metastases had a 10-year survival of only 30 percent compared with a 15-year survival of 83 percent in those without liver metastases",
"     </li>",
"     <li>",
"      Patients with lymph node metastases had the same mortality as those who were free of visceral metastases",
"     </li>",
"     <li>",
"      Patients with MEN 1 had a significantly lower rate of metastasis at the time of initial diagnosis (6 percent); their high overall survival rate (100 percent at 20 years) reflected this fact",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The level of fasting serum gastrin (FSG) at the time of initial diagnosis may provide an indication of disease extent and estimated prognosis in patients with sporadic ZES. In a follow-up report of 239 patients with ZES, the level of preoperative FSG correlated with tumor size and presence of lymph nodes and liver metastases (as found at exploration), as well as primary site (pancreas tumors associated with highest levels of FSG) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/37\">",
"     37",
"    </a>",
"    ]. The five-year survival rates for patients with mild (0 to 499",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    moderate (500 to 1000",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    or severe elevations (&gt;1000",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    of FSG were 94, 92, and 86 percent, respectively. The corresponding 10-year survival rates were 86, 87, and 73 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence from which to make recommendations for follow-up after resection of a gastrinoma. Guidelines from the National Comprehensive Cancer Network based upon expert consensus include the following recommendations for follow-up after treatment of an islet cell tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6968/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three and six months postresection &mdash; History and physical examination, serum gastrin, and computed",
"      <span class=\"nowrap\">",
"       tomography/magnetic",
"      </span>",
"      resonance imaging.",
"     </li>",
"     <li>",
"      Long-term &mdash; History and physical examination with tumor markers every six to 12 months for years 1 to 3, and as clinically indicated thereafter. Imaging studies are recommended only as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy is the current standard of care for most patients with Zollinger-Ellison syndrome (ZES) as part of the MEN 1 syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Treatment\"",
"      </a>",
"      .) By contrast, we recommend that (in addition to medical therapy) patients with a sporadic gastrinoma and without evidence of metastatic spread of disease be treated with exploratory laparotomy with curative intent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In addition to eliminating or at least decreasing the need for antisecretory medical therapy, successful resection of sporadic gastrinomas protects against the possibility of eventual morbidity and death from metastatic spread of the tumor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of medical management in ZES is to limit the clinical manifestations and complications of peptic ulcer disease. We recommend that patients with ZES should be started on a high dose proton pump inhibitor such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      60 mg daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      120 mg daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      45 mg daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"       rabeprazole",
"      </a>",
"      60 mg daily, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      120 mg daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The recommended dose for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"       dexlansoprazole",
"      </a>",
"      has not been established. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality from gastrinomas depends largely upon whether the tumor is benign or malignant, and the extent of disease involvement. Metastatic gastrinoma is the most common cause of morbidity and mortality in patients with ZES. Unfortunately, the current modalities for treatment of metastatic disease have been of limited benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with limited, resectable liver-isolated metastatic gastrinoma, we recommend surgical resection of the hepatic metastases along with the primary tumor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although the majority of cases will not be cured by surgery, given the slow-growing nature of the tumor, extended survival is sometimes possible. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other treatment options for patients with unresectable hepatic-predominant metastatic disease include embolization, chemoembolization, RFA, and cryoablation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Liver-directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of somatostatin analogs for patients with symptomatic metastatic gastrinoma is unpredictable, but some patients with somatostatin receptor-positive tumors may benefit. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Somatostatin analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other systemic therapy approaches (interferon, chemotherapy, targeted radiotherapy) are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/1\">",
"      Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/2\">",
"      Quatrini M, Castoldi L, Rossi G, et al. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol 2005; 39:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/3\">",
"      Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/4\">",
"      Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/5\">",
"      Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/6\">",
"      Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/7\">",
"      Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/8\">",
"      Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006; 23:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/9\">",
"      Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/10\">",
"      Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000; 118:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/11\">",
"      Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/12\">",
"      Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/13\">",
"      Norton JA. Surgical treatment and prognosis of gastrinoma. Best Pract Res Clin Gastroenterol 2005; 19:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/14\">",
"      Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 1992; 215:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/15\">",
"      Norton JA, Fraker DL, Alexander HR, Jensen RT. Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. Ann Surg 2012; 256:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/16\">",
"      Jensen RT. Should the 1996 citation for Zollinger-Ellison syndrome read: \"Acid-reducing surgery in, aggressive resection out\"? Am J Gastroenterol 1996; 91:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/17\">",
"      Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/18\">",
"      Ojeaburu JV, Ito T, Crafa P, et al. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci 2011; 56:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/19\">",
"      McArthur KE, Richardson CT, Barnett CC, et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol 1996; 91:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/20\">",
"      Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/21\">",
"      Jaskowiak NT, Fraker DL, Alexander HR, et al. Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery 1996; 120:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/22\">",
"      Contessa JN, Griffith KA, Wolff E, et al. Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys 2009; 75:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/23\">",
"      Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007; 85:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/24\">",
"      Tennvall J, Ljungberg O, Ahr&eacute;n B, et al. Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J Surg Oncol 1992; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/25\">",
"      Torrisi JR, Treat J, Zeman R, Dritschilo A. Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987; 60:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/26\">",
"      Gery B, Roussel A, Valla A. Usefulness of radiotherapy in the treatment of advanced gastrinomas. Radiother Oncol 1993; 27:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/27\">",
"      Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998; 16:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/28\">",
"      Saijo F, Naito H, Funayama Y, et al. Octreotide in control of multiple liver metastases from gastrinoma. J Gastroenterol 2003; 38:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/29\">",
"      Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/30\">",
"      Burgess JR, Greenaway TM, Parameswaran V, Shepherd JJ. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. Cancer 1999; 86:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/31\">",
"      Gaztambide S, Vazquez JA. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma. J Endocrinol Invest 1999; 22:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/32\">",
"      Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/33\">",
"      Deol ZK, Frezza E, DeJong S, Pickleman J. Solitary hepatic gastrinoma treated with laparoscopic radiofrequency ablation. JSLS 2003; 7:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/34\">",
"      Leimer M, Kurtaran A, Smith-Jones P, et al. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998; 39:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/35\">",
"      Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/36\">",
"      Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6968/abstract/37\">",
"      Berger AC, Gibril F, Venzon DJ, et al. Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome. J Clin Oncol 2001; 19:3051.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2584 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-F9B63D4400-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6968=[""].join("\n");
var outline_f6_51_6968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reoperation for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIATION THERAPY FOR NONSURGICAL CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THERAPY OF METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Liver-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hepatic artery embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - RFA and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotherapy and novel treatment approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2584|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/57/32671\" title=\"algorithm 1\">",
"      Algorithm for treatment of metastatic neuroendocrine tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_51_6969="Actinic damage renal transplant";
var content_f6_51_6969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69827%7EDERM%2F72634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69827%7EDERM%2F72634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Actinic damage in a renal transplant patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal transplant patient with actinically damaged skin studded with verruca, actinic keratoses, and early squamous cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple actinic keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperkeratotic lesions are present on the dorsal hands and forearms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6969=[""].join("\n");
var outline_f6_51_6969=null;
var title_f6_51_6970="Castleman's disease";
var content_f6_51_6970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Castleman's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Jennifer R Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/51/6970/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/51/6970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Castleman's disease (CD, angiofollicular lymph node hyperplasia) is a lymphoproliferative disorder associated in a subset of cases with the human immunodeficiency virus (HIV) and human herpesvirus 8 (HHV-8). CD comprises at least two distinct diseases (localized and multicentric) with very different prognoses. It is also associated with a number of malignancies, including Kaposi sarcoma, non-Hodgkin lymphoma, Hodgkin lymphoma, and POEMS syndrome.",
"   </p>",
"   <p>",
"    CD was first described in 1956 by Benjamin Castleman and colleagues, who identified a series of patients with solitary hyperplastic mediastinal lymph nodes containing small, hyalinized follicles and a marked interfollicular vascular proliferation (hyaline vascular variant of CD) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/1\">",
"     1",
"    </a>",
"    ]. The same investigators later identified lymph nodes with a similar vascular proliferation associated with large hyperplastic germinal centers and sheets of interfollicular plasma cells. Hyalinized follicles were present in some, but not all, such cases, which were called the plasma cell variant of CD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Approximately 10 to 20 percent of all cases were of the plasma cell variant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/3\">",
"     3",
"    </a>",
"    ], while a small percent had a mixed histologic appearance with features of both the hyaline vascular and plasma cell subtypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the patients described in these early papers had localized disease, which is now termed unicentric Castleman's disease (UCD). UCD is associated with systemic symptoms in a subset of cases.",
"     </li>",
"     <li>",
"      A multicentric form of CD (MCD) was recognized in 1978 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/4\">",
"       4",
"      </a>",
"      ]. MCD is a systemic disease with generalized peripheral lymphadenopathy, hepatosplenomegaly, frequent fevers, and night sweats that is usually associated with the plasma cell variant [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/5\">",
"       5",
"      </a>",
"      ]. Unlike UCD, MCD is strongly associated with immunosuppression and HHV-8 infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/6-11\">",
"       6-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since CD is rare, there are no reliable estimates of its incidence in the population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/12\">",
"     12",
"    </a>",
"    ]. This topic review will discuss the pathology, pathogenesis, clinical features, and treatment of CD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A review of diseases associated with HHV-8 infection and the virology of HHV-8 are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link\">",
"     \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD is characterized by nodal expansions that usually leave the structure of the underlying lymph node at least partially intact. Three major variants are recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       The hyaline vascular variant",
"      </strong>",
"      is characterized by the presence of abnormal follicles with atrophic or \"regressed\" germinal centers surrounded by broad mantle zones of small lymphocytes, which are often present in an \"onion-skin\" arrangement. Often two or more closely adjacent atrophic germinal centers are encircled by a single mantle zone (\"double germinal centers\"). The regressed germinal centers, which may become hyalinized, actually contain numerous follicular dendritic cells, rather than proliferating blood vessels, as Castleman initially thought. Indeed, the characteristic morphology is produced by these follicular dendritic cells, whose concentric processes are responsible for the \"onion-skin\" appearance. The interfollicular lymphoid tissue contains numerous small blood vessels known as high endothelial venules. Sinuses are typically obliterated [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/1,3,15\">",
"       1,3,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       The plasma cell variant",
"      </strong>",
"      has hyperplastic germinal centers and often some regressed or \"hyaline vascular\" follicles as well; the interfollicular region is hypervascular and contains sheets of plasma cells. Sinuses may be patent, particularly in multicentric cases. Other disorders that can be associated with hyperplastic reactive lymph nodes containing increased numbers of plasma cells, such as rheumatoid arthritis and other connective tissue diseases, need to be excluded before this diagnosis can be entertained [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       HHV8+ Castleman's disease",
"      </strong>",
"      is characterized by preservation of nodal architecture and increased numbers of follicles that vary from hyperplastic to regressed. The interfollicular region contains proliferating blood vessels and mature plasma cells, similar to the plasma cell type. In contrast to the localized HHV8-negative plasma cell variant, in HHV8+ CD increased numbers of immunoblasts (called plasmablasts in some reports) are present in the outer mantle zones of the hyperplastic follicles and sometimes in the germinal centers as well [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. These cells may coalesce to form so-called \"microlymphomas\", a controversial term that has been used by some to describe the accumulation of plasmablasts that are monotypic with respect to immunoglobulin light chain expression, yet polyclonal when evaluated for immunoglobulin gene rearrangements [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/18\">",
"       18",
"      </a>",
"      ], a highly unusual combination of findings that are described in more detail below. In most cases with these morphologic features, frank HHV8+ plasmablastic B-cell lymphoma eventually develops [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic features of lymph nodes from patients with CD, namely germinal center hyperplasia, the accumulation of immunoblasts and plasma cells, and increased vascularity, are best viewed as exaggerations of the types of reactive changes that can be seen in response to normal antigenic stimuli. Indeed, similar histologic changes are seen in other disorders associated with chronic immune activation, including autoimmune diseases, rheumatoid arthritis, and various congenital immunodeficiency states [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/5\">",
"     5",
"    </a>",
"    ]. The mantle zone lymphocytes in both categories of CD are polyclonal IgM or IgD-expressing cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. The plasma cells in the interfollicular areas are generally also polyclonal. Localized clonal expansions are sometimes seen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], but do not appear to affect prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Human herpesvirus 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major advance both in defining and understanding the pathogenesis of MCD came with the identification of the Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8) in more than half of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/8\">",
"     8",
"    </a>",
"    ]. HHV-8 is a gamma herpesvirus similar to Epstein-Barr virus and herpesvirus saimiri that has been found in both endemic and HIV-associated Kaposi sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/7,25\">",
"     7,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two major lymphoproliferative disorders are associated with this virus, primary effusion lymphomas (PEL) and MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/9,26-30\">",
"     9,26-30",
"    </a>",
"    ]. As mentioned above, the latter may progress to a B-cell plasmablastic lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16\">",
"     16",
"    </a>",
"    ]. A third rare, but apparently distinctive, B-cell proliferation, referred to as germinotropic lymphoproliferative disorder, has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/31\">",
"     31",
"    </a>",
"    ]. Of some possible pathogenic significance, HHV-8+ MCD and plasmablastic lymphoma are not associated with EBV infection, whereas in PEL and germinotropic lymphoproliferative disorder, co-infection of the neoplastic B cells by HHV-8 and EBV is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link&amp;anchor=H3#H3\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pathogenetic relationship between MCD and HHV-8 was sought because of the well-recognized clinical association of Kaposi sarcoma and MCD (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Multicentric Castleman's disease'",
"    </a>",
"    below). In one study, HHV-8 sequences were found in lymph nodes in all 14 cases of HIV+ MCD and in 7 of 17 cases of HIV-negative MCD, compared with 1 of 51 HIV-negative reactive lymph nodes and 3 of 17 HIV+ reactive lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]. Since then, other studies have confirmed that HHV-8 is universally found in HIV+ MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/32\">",
"     32",
"    </a>",
"    ] and in approximately 40 to 50 percent of HIV-negative MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/6,32\">",
"     6,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between HIV-negative MCD and HHV-8 may vary with the prevalence of HHV-8 in the population. In Japan, where the seroprevalence of HHV-8 is extremely low, HHV-8 was found only in HIV-infected patients with MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, UCD is rarely, if ever, associated with HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/25,29,34,35\">",
"     25,29,34,35",
"    </a>",
"    ], suggesting that it is a different disease with a unique pathogenesis.",
"   </p>",
"   <p>",
"    Immunohistochemical stains for virally encoded antigens have demonstrated that HHV-8 is present in approximately 10 to 30 percent of the mantle zone lymphoid cells of HHV-8+ MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. These cells have immunoblastic morphology, are variably positive for CD20, and express the transcription factor",
"    <span class=\"nowrap\">",
"     MUM1/IRF4",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16,17,36-38\">",
"     16,17,36-38",
"    </a>",
"    ]. Curiously, the HHV-8 infected cells always express high levels of cytoplasmic IgM lambda immunoglobulin, which is consistent with in vitro studies showing that HHV8 preferentially establishes stable infection in tonsillar B cells expressing IgM lambda immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/39\">",
"     39",
"    </a>",
"    ]. Somatic hypermutation of the Ig genes is not observed, which may indicate an origin from a naive B cell or, alternatively, from an IgM-expressing memory B cell; IgM memory cells have been identified in tonsils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/39\">",
"     39",
"    </a>",
"    ], the anatomic site where primary infection with HHV8 is believed to occur. Immunoblasts with these features are absent from UCD and HHV8-negative MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17\">",
"     17",
"    </a>",
"    ]. The interfollicular plasma cells, which are not infected with HHV-8 in MCD, express IgG or IgA immunoglobulins and are polytypic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-8-infected immunoblasts are highly proliferative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17\">",
"     17",
"    </a>",
"    ] and (as described above) may coalesce to form so-called \"microlymphomas,\" or give rise to frank plasmablastic lymphoma. Despite their monotypic IgM lambda expression, the HHV8+ proliferation in MCD has polyclonal immunoglobulin gene rearrangements, even in most of those that have progressed to \"microlymphomas\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, HHV-8 genomes within MCD lesions are also polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmablastic lymphomas arising out of HHV-8+ MCD are monoclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. It is hypothesized that the hyperproliferative state induced by HHV-8 permits the accumulation of new mutations in the genomes of the infected B immunoblasts. Positive selection for clones bearing mutations that enhance growth and survival then allows an initially reactive process to evolve over time into an overt lymphoma. This model is similar to that proposed for the continuum of lymphoproliferative disorders that are associated with Epstein-Barr virus in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both UCD and MCD have been linked to excessive release of interleukin (IL)-6 or similar polypeptides. Early studies linked local production of IL-6 to the systemic manifestations of UCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], since lymph node excision resulted in relief of symptoms along with a decrease in IL-6 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/41\">",
"     41",
"    </a>",
"    ]. The precise cells within the lymph node responsible for production of IL-6 have remained elusive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/15\">",
"     15",
"    </a>",
"    ]; candidate cells include blastic B-cells of the germinal centers, follicular dendritic cells, or cells present in the interfollicular regions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In mice, transgenic expression of IL-6 by hematopoietic progenitor cells results in a syndrome similar to MCD, with peripheral lymphadenopathy, extensive plasma cell infiltration of lymphoid tissues, splenomegaly, anemia, and hypergammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Particularly during lytic (replicative) infection, but to a lesser degree during latent infection as well, HHV-8+ B cells secrete a virally encoded form of IL-6 (vIL-6) that activates the human IL-6 receptor. In addition to HHV8+ CD, vIL-6 is also secreted from primary effusion lymphomas, but only rarely in Kaposi sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/37,38,44,45\">",
"     37,38,44,45",
"    </a>",
"    ]. Between 5 and 25 percent of the HHV-8-negative infected immunoblasts in the mantle zone of MCD lymph nodes express vIL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/37,38,44,45\">",
"     37,38,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-level expression of vIL-6 in fibroblasts injected into athymic mice has reproduced a syndrome similar to MCD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While vIL-6 induces the proliferation of human myeloma cell lines, it is only about",
"      <span class=\"nowrap\">",
"       1/1000",
"       <sup>",
"        th",
"       </sup>",
"      </span>",
"      as potent as human IL-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/44,47\">",
"       44,47",
"      </a>",
"      ]. Of interest, transgenic mice constitutively expressing vIL-6 spontaneously develop key features of human plasma cell-type MCD, including splenomegaly, lymphadenopathy, hypergammaglobulinemia, and plasmacytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/48\">",
"       48",
"      </a>",
"      ]. This phenotype does not occur, however, if the vIL-6 transgene is crossed into IL-6 knockout mice, indicating that endogenous IL-6 is an important cofactor in this model and possibly in human HHV-8+ MCD as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, due in part to its greater potency, human IL-6 (hIL-6) may play a larger role in MCD than vIL-6. Several sources of hIL-6 have been proposed in MCD. HHV-8 gene products, such as LANA-1 and vFLIP, induce the expression of hIL-6 in HHV-8 infected B cells through activation of the transcription factors NF-kB and AP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Alternatively, another model proposes that vIL-6 secreted by HHV-8+ cells induces vascular endothelial growth factor (VEGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/46,53\">",
"     46,53",
"    </a>",
"    ], and that VEGF in turn induces hIL-6 production by endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important pathogenic role for hIL-6 is consistent with effects of neutralizing anti-hIL-6 antibodies. Antibodies that specifically inhibit hIL-6 can result in the resolution of the systemic symptoms and hypergammaglobulinemia of MCD (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Inhibition of interleukin-6'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In addition, in two patients with MCD, serum hepcidin levels fell rapidly following administration of an IL-6 receptor antibody, with subsequent near-normalization of hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/56\">",
"     56",
"    </a>",
"    ]. These initial results suggest that IL-6-induced hepcidin overproduction is involved in the pathophysiology of the anemia commonly observed in this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic patients with HHV8+ CD have HHV-8 viral loads that are 2 logs greater than asymptomatic HHV8+ patients; the increased viral load correlates with increased serum levels of IL-6 and IL-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/57\">",
"     57",
"    </a>",
"    ]. On the other hand, this degree of increased serum HHV-8 viral load is not seen in patients with active Kaposi sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these data may address the pathogenesis of HHV-8+ MCD, they do not advance our understanding of the pathogenesis of UCD or HHV-8-negative MCD. It is likely that these subtypes have a different, unidentified source of immune stimulation that leads to local and occasional systemic overproduction of hIL-6 and other cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UNICENTRIC CASTLEMAN'S DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unicentric Castleman's disease (UCD) is most often an isolated benign lymphoproliferative disorder of young adults that is unassociated with HHV-8 infection and generally curable with surgical resection. The largest published series included 81 cases; approximately 90 percent were of the hyaline vascular variant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/3\">",
"     3",
"    </a>",
"    ]. The vast majority of patients were asymptomatic and their disease was identified incidentally on imaging studies. The median age was 35, equally divided between males and females. The median size of the lesion was 5 to 9 cm; the vast majority of the 81 lesions were in the mediastinum and lung (72) or neck (five). Of the 183 reported cases in the literature, including this series, 71 percent of the lesions were in the chest. Peripheral lymphadenopathy was unusual and laboratory abnormalities were seen in less than 25 percent.",
"   </p>",
"   <p>",
"    Ten to 20 percent of patients with UCD present with the plasma cell type; their characteristics are similar to those of patients presenting with the hyaline vascular type except that approximately 50 percent have systemic findings of anemia, elevated sedimentation rate, hypergammaglobulinemia, and bone marrow plasmacytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete resection (eg, resective or debulking surgery) of the involved node in either type of UCD (ie, hyaline vascular or plasma cell types) is curative and has been considered the gold standard approach for the treatment of UCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/59\">",
"     59",
"    </a>",
"    ], with no reported recurrences in any series. Systemic symptoms, if present, also resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/3,17,45,60-62\">",
"     3,17,45,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients whose lesions cannot be completely resected, outcomes remain favorable. Partially resected masses may remain stable and asymptomatic for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/3,60,61\">",
"     3,60,61",
"    </a>",
"    ]. Radiation treatment with approximately 30 to 45 Gy can result in complete and partial remission rates of 40 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was reported in a single patient with recurrent chest pain due to an unresectable tumor mass encompassing the right main pulmonary artery and main bronchus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H148951866\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;UCD may be associated with an increased risk of lymphoma. Of 48 reported cases of UCD, three developed B-cell non-Hodgkin lymphoma (NHL), one developed Hodgkin lymphoma, and two others amyloidosis, despite complete resection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17,45,60-62,64\">",
"     17,45,60-62,64",
"    </a>",
"    ]. A series of eight cases of UCD associated with NHL has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/65\">",
"     65",
"    </a>",
"    ]. The two diagnoses were concurrent in three, with a mean interval of 46 months between the diagnosis of UCD and the subsequent NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/65\">",
"     65",
"    </a>",
"    ]. Hodgkin lymphoma has also been reported with UCD-like histologic changes in the same lymph node [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 15 percent of instances of paraneoplastic pemphigus are associated with UCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"     \"Paraneoplastic pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MULTICENTRIC CASTLEMAN'S DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HIV-associated MCD was calculated from a prospective HIV database with 56,202 patient-years of follow-up and compared with that of Kaposi sarcoma (KS) during the same time period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/67\">",
"     67",
"    </a>",
"    ]. The incidence of MCD increased over the time periods pre-HAART (1983-1996), early-HAART (1997-2001), and later HAART (2002-2007) eras and was 0.6, 2.8, and 8.3",
"    <span class=\"nowrap\">",
"     cases/10,000",
"    </span>",
"    patient-years, respectively. In contrast, the incidence of KS decreased markedly during the same three time periods, and was 520, 85, and 63",
"    <span class=\"nowrap\">",
"     cases/10,000",
"    </span>",
"    patient-years, respectively. The explanation for the apparent increase in MCD during the HAART era is uncertain. One possibility is that subtle forms of immune dysregulation are of greater importance in the etiology of HIV-associated MCD than immunosuppression per se. On multivariate analysis, risk factors for the development of MCD included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nadir CD4 count",
"      <span class=\"nowrap\">",
"       &gt;200/microL",
"      </span>",
"     </li>",
"     <li>",
"      Increased age",
"     </li>",
"     <li>",
"      No previous HAART exposure",
"     </li>",
"     <li>",
"      Non-Caucasian ethnicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multicentric Castleman's disease (MCD) present at a median age between 52 and 65, although those who are HIV-infected tend to be younger [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/61,62,64,68-73\">",
"     61,62,64,68-73",
"    </a>",
"    ]. Fifty to 65 percent are male. Symptoms are common but nonspecific, and are suggestive of an inflammatory illness. Patients present with fever, which is nearly universal, as well as night sweats, weight loss, and weakness or fatigue. Less than 10 percent are asymptomatic.",
"   </p>",
"   <p>",
"    The pace of disease development in MCD is variable, with some patients reporting a slow onset over a few years and others becoming acutely ill [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/5,68\">",
"     5,68",
"    </a>",
"    ]. HIV-infected patients tend to pursue an acute course, with a median duration of symptoms at the time of diagnosis of MCD of three months (range: 0.5 to 24 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/72\">",
"     72",
"    </a>",
"    ]. About 60 percent of HIV-infected patients with MCD complain of cough or dyspnea, sometimes associated with non-infectious pulmonary interstitial lymphocytic and plasma cell infiltrates in the absence of infection, with an overall picture that closely resembles lymphocytic interstitial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/15,70,72,74\">",
"     15,70,72,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study analyzed factors that predicted for the onset of active disease in 52 HIV infected patients with MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/75\">",
"     75",
"    </a>",
"    ]. Although a younger age (&lt;50 years) was associated with active",
"    <span class=\"nowrap\">",
"     disease/relapse,",
"    </span>",
"    the strongest association on multivariate analysis was with rising plasma levels of HHV-8 DNA (HR 2.9; 95% CI 1.3-6.7).",
"   </p>",
"   <p>",
"    Peripheral lymphadenopathy is virtually always present in MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/5,61,62,68,76\">",
"     5,61,62,68,76",
"    </a>",
"    ]. It is frequently generalized and is associated with hepatosplenomegaly in the vast majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/77\">",
"     77",
"    </a>",
"    ]. Only about 10 percent of HIV-negative cases have mediastinal or abdominal lymphadenopathy at presentation, but with disease progression, or in HIV-infected patients at diagnosis, approximately 50 percent have lymph node involvement of these sites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1997782\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on imaging are nonspecific, but may include the following (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87767 \" href=\"RADIOL_87767\">",
"     image 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chest radiograph",
"      </strong>",
"      &mdash; In patients with MCD, the chest radiograph may show bilateral reticular or ground glass opacities, mediastinal widening,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bilateral pleural effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/78\">",
"       78",
"      </a>",
"      ]. Less commonly, lung nodules or rounded areas of consolidation are seen.",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography of the chest",
"      </strong>",
"      &mdash; On computed tomography (CT) of the chest, most patients with MCD have multiple enlarged mediastinal and hilar lymph nodes (1 to 3 cm diameter) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/74,78\">",
"       74,78",
"      </a>",
"      ]. A spectrum of lung parenchymal findings may be seen, including subpleural nodules, interlobular septal thickening, peribronchovascular thickening, ground glass opacities, and patchy, rounded areas of consolidation. Small to moderate bilateral pleural effusions may be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16947056\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical laboratory abnormalities in MCD include nearly universal anemia, hypoalbuminemia, hypergammaglobulinemia, and an elevated erythrocyte sedimentation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/76\">",
"     76",
"    </a>",
"    ]. In one report, these laboratory abnormalities were associated with increased levels of a variety of cytokines, most notably IL-10 and IL-6, but also IL-5, IL-8, IL-12 and interferon-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258355\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MCD is made on tissue examination of a resected lymph node. The most abnormal node is selected if multiple node groups are involved. If no single node predominates, the choice in descending order of preference is supraclavicular, neck, axilla, and groin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link&amp;anchor=H28#H28\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\", section on 'Lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On biopsy, the majority of lymph nodes show the plasma cell or mixed",
"    <span class=\"nowrap\">",
"     hyaline-vascular/plasma",
"    </span>",
"    cell variants, with less than 10 percent of cases showing only the hyaline vascular variant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/61,62,64,68,69,71\">",
"     61,62,64,68,69,71",
"    </a>",
"    ]. Lymph nodes from HIV-infected patients are nearly always positive for HHV-8 and 40 percent contain coexistent Kaposi sarcoma (KS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/70\">",
"     70",
"    </a>",
"    ]. KS and MCD may also be found together in lymph nodes taken from HIV-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/71,79-81\">",
"     71,79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16947063\">",
"    <span class=\"h2\">",
"     Disease progression and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different patterns of disease progression have been described in MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/68,71\">",
"     68,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An indolent form of MCD sometimes persists for months to a few years without worsening.",
"     </li>",
"     <li>",
"      An episodic relapsing form may be aggressive for a short period and then remit spontaneously or in response to treatment, only to recur at a later time.",
"     </li>",
"     <li>",
"      A rapidly progressive form that can lead to death within weeks may be more common in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17,82\">",
"       17,82",
"      </a>",
"      ]. Initiation of highly active anti-retroviral therapy in patients who are positive for both HIV and HHV-8 may increase the likelihood of developing acute, fulminant MCD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/82\">",
"       82",
"      </a>",
"      ], but this remains to be confirmed.",
"     </li>",
"     <li>",
"      In a study of 52 subjects with a histologic diagnosis of HIV+ MCD, the strongest predictor for disease relapse was a rise in the plasma levels of HHV-8 DNA [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median survival of patients with MCD in the pre-HIV era was 26 to 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/68,71\">",
"     68,71",
"    </a>",
"    ]. In the two largest series of HIV+ MCD patients (n = 28), the outcome was even poorer, with an overall mortality of 70 to 85 percent and a median survival of 8 to 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17,70\">",
"     17,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected patients with MCD are almost universally infected with HHV-8. At present it is unclear whether the poor outcomes in this group are primarily due to HIV alone, to HHV-8 alone, or to an interaction between the two. The available literature suggests that HHV-8 infection may be the more important factor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of six MCD patients identified in the literature as HIV-negative and HHV8-negative, four are alive and reportedly well, with two deaths due to lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17,45,65,83\">",
"       17,45,65,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of 10 patients identified as HIV-negative and HHV8+, seven have died, including several within a few months of diagnosis. Three of 10 developed lymphoma and 4 of 10 had Kaposi sarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17,45,65\">",
"       17,45,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal cases of MCD are associated with fulminant infection, progressive disease, or related malignancies. Of the 50 patients reported before the HIV era or in whom HIV status was unknown, 38 percent developed serious infections, with 70 percent of infections directly contributing to death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/62,64,68,69,71\">",
"     62,64,68,69,71",
"    </a>",
"    ]. Many patients have been reported to die of progressive disease with multi-organ system failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/68,69,71\">",
"     68,69,71",
"    </a>",
"    ]. Whether these patients died of undetected conversion to lymphoma or uncontrolled HHV-8 infection is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many deaths are due to the well-described association of Castleman's disease with other malignancies, particularly Kaposi sarcoma (KS) and hematologic malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Kaposi sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older reports, Kaposi sarcoma (KS) was noted in approximately 13 percent of patients with MCD; KS may be diagnosed beforehand, concomitantly, or afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/5\">",
"     5",
"    </a>",
"    ]. Among HIV-infected patients fully 70 percent of those with MCD have KS at some time during their course [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/17,70,82,84\">",
"     17,70,82,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Non-Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma (NHL) is significantly associated with MCD. Approximately 15 to 20 percent of MCD patients present with or develop aggressive NHL, most commonly some variant of diffuse large B-cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/62,65,68,69,71\">",
"     62,65,68,69,71",
"    </a>",
"    ]. The incidence of NHL reported in retrospective series does not appear to vary with HIV status, but is limited by small numbers. The reported death rate is 85 percent for patients who develop NHL together with MCD, despite use of standard therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/65,71\">",
"     65,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of NHL in this setting is not entirely clear, but at least some cases appear to be related to uncontrolled HHV-8 infection. A prospective cohort study of 60 HIV-infected patients with MCD found that 14 developed NHL at up to 76 months after MCD diagnosis, for an actuarial two-year incidence of 24 percent, 15-fold greater than that expected for HIV-infected patients in general [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/84\">",
"     84",
"    </a>",
"    ]. All of the NHLs were positive for HHV-8, with about half having a phenotype similar to primary effusion lymphoma, and half similar to plasmablastic lymphoma.",
"   </p>",
"   <p>",
"    Of interest, the plasmablastic lymphomas have morphology similar to the HHV8+ immunoblasts (or \"plasmablasts\") found in the mantle zone of MCD lymph nodes (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above). Four of these plasmablastic lymphomas presented with a fulminant leukemic phase and were fatal within one week. The median survival from diagnosis of NHL in the HIV+ HHV8+ patients was one month [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/84\">",
"     84",
"    </a>",
"    ]. However, not all NHL that is associated with CD is HHV-8 related, since cases have been reported in unicentric Castleman&rsquo;s disease and in HHV8-negative MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/45,60,65\">",
"     45,60,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common than non-Hodgkin lymphoma, multiple reports in the literature have associated Hodgkin lymphoma with both UCD and MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/65,79,85-91\">",
"     65,79,85-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     POEMS syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another well-described constellation of symptoms associated with MCD is the POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes; also called osteosclerotic myeloma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35049?source=see_link\">",
"     \"POEMS syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About 75 to 100 percent of patients with POEMS syndrome have a monoclonal gammopathy; 87 to 98 percent have sclerotic bone lesions; and up to 20 percent of patients having plasma cell infiltration of the bone marrow. Conversely, about 50 percent of patients with POEMS syndrome have an associated MCD of the plasma cell type [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of patients with POEMS and MCD, approximately 80 percent have evidence of HHV-8 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. Patients with POEMS syndrome almost invariably have lambda light-chain bearing paraproteins, which is of interest given the lambda light-chain restriction of the \"plasmablasts\" in HHV8-associated MCD. In contrast, only 10 to 15 percent of patients who have POEMS without MCD show evidence of HHV-8 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study in which four of five patients with the POEMS syndrome also had MCD, increased levels of interleukin (IL)-1 beta were noted in 13 of 13 serum samples, while IL-6 was increased in seven [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/96\">",
"     96",
"    </a>",
"    ]. These similarities between POEMS syndrome and MCD suggest a common underlying mechanism in at least some cases, perhaps infection with HHV-8 with resulting increased cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21405924\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available literature on the treatment of MCD consists mainly of single case reports and case series, with no randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/99\">",
"     99",
"    </a>",
"    ]. However, an increasing body of evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , alone or in conjunction with cytostatic agents, is able to stabilize patients and, as initial therapy, can induce durable remissions in a high percentage of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/76,100\">",
"     76,100",
"    </a>",
"    ]. The safety profile is adequate, with the caveat that exacerbations of cutaneous Kaposi sarcoma can be seen and some deaths due to respiratory complications have been reported. Rituximab is therefore emerging as the likely treatment of choice for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/72,77\">",
"     72,77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H148951866\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , the use of combination chemotherapy is primarily reserved for patients with aggressive disease (eg, evidence for organ damage, poor performance status) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/77\">",
"     77",
"    </a>",
"    ]. For patients with poor performance status who are not candidates for aggressive therapy, the preferred regimens are glucocorticoids or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    for palliation of symptoms. Following disease stabilization with single agent chemotherapy, discontinuation of chemotherapy followed by treatment with rituximab may result in long-term disease stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapies with short-term efficacy in suppressing symptoms include antiviral drugs and antibodies that block IL-6 activity. However, there is no evidence that these therapies are more than palliative.",
"   </p>",
"   <p>",
"    While surgical removal of lymph nodes is curative in unicentric disease, it does",
"    <strong>",
"     not",
"    </strong>",
"    have a role in the treatment of MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/59\">",
"     59",
"    </a>",
"    ]. However, splenectomy can result in transient symptomatic improvement in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/68,70\">",
"     68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148951866\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoclonal anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , alone or in combination with chemotherapy, has significant activity in HIV+ as well as HIV-negative MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/72,76,77,100-108\">",
"     72,76,77,100-108",
"    </a>",
"    ], even when used as salvage therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/109\">",
"     109",
"    </a>",
"    ]. These clinical responses have been associated with significant decreases in plasma levels of IL-5, IL-6, and IL-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/102,110\">",
"     102,110",
"    </a>",
"    ]. Some HIV-infected patients have had exacerbation of their Kaposi sarcoma lesions after rituximab therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/76,104,111\">",
"     76,104,111",
"    </a>",
"    ], but others have undergone remission [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/103\">",
"     103",
"    </a>",
"    ]. Accordingly, care must be taken with rituximab in HIV positive patients whose viral load is poorly controlled, who have low CD4 counts or active KS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5347459\">",
"    <span class=\"h4\">",
"     Use in HIV+ patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in HIV-infected patients with MCD has only been evaluated in observational studies. Part of the rationale for these studies was frequent disease recurrence following the cessation of single agent chemotherapy (see",
"    <a class=\"local\" href=\"#H16947712\">",
"     'Chemotherapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study evaluated 24 HIV-infected patients with MCD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/101\">",
"       101",
"      </a>",
"      ]. All had stable disease on treatment with single agent chemotherapy for a median time of 13 months, with at least one disease recurrence after an attempt to discontinue treatment. Chemotherapy was discontinued 6 to 10 days before the first of four weekly intravenous infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m2).",
"      </span>",
"      The primary endpoint, sustained remission (SR) off treatment at 60 days, was achieved in 22 of the 24 patients (92 percent), with 17 (71 percent) in SR without specific treatment at one year. Mild exacerbation of Kaposi sarcoma (KS) lesions was noted in 8 of the 12 patients with previous KS.",
"     </li>",
"     <li>",
"      In a second study, 21 consecutive patients with symptomatic HIV+ MCD were treated with four weekly IV infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"      and followed for a median of 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/76\">",
"       76",
"      </a>",
"      ]. Of the 20 patients completing the entire course of treatment, all achieved resolution of symptoms and fever following the fourth infusion, with partial responses and stable disease in 67 and 29 percent, respectively. Two-year overall survival was 95 percent, with one- and two-year relapse-free survivals of 92 and 79 percent, respectively. Plasma HHV-8 was detectable in 80 percent of patients at diagnosis, in 20 percent one month after rituximab treatment, and in 10 percent three months after treatment. CD4 count and HIV viral load remained stable. No grade 3 or 4 toxicities were observed, but, as noted in other studies, Kaposi sarcoma progressed during rituximab treatment in 4 of 11 (36 percent) patients who had cutaneous disease at the time of diagnosis.",
"     </li>",
"     <li>",
"      A third study reported on the treatment of 49 patients with newly diagnosed HIV+ MCD using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      with (14 patients) or without (35 patients)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/72\">",
"       72",
"      </a>",
"      ]. Etoposide was added for higher risk patients and resulted in similar outcomes as rituximab alone in the lower risk patients. Overall survival for the whole group at two and five years was 94 and 90 percent, respectively, with two- and five-year progression-free survivals of 85 and 61 percent, respectively. All eight patients with symptomatic, histologically-confirmed relapsed MCD responded to re-treatment with rituximab-based therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two retrospective analyses of treatment outcomes in HIV+ patients with MCD have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in 52 patients with HIV+ MCD, those who had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -based regimens had significantly higher complete remission rates (10 of 11, 91 percent) than those receiving chemotherapy with or without antiviral therapy (9 of 22, 41 percent) and also had significantly longer overall survival (not reached versus 5.1 years, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/100\">",
"       100",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The second report was from a single-center prospective cohort of 113 patients with HIV+ MCD. At a median follow-up of 4.2 years, the incidence of development of non-Hodgkin lymphoma was 4.2 and 69.6 per 1000 person-years for those who did (R+) or did not (R-) receive rituximab-based treatment, respectively (hazard ratio 0.09; 95% CI 0.01-0.70) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/111\">",
"       111",
"      </a>",
"      ]. Flares of KS occurred in one-third of the R+ patients who had previously stable KS lesions. Two- and five-year overall survivals were 93 and 90 percent, respectively, for the R+ patients, and 68 and 47 percent, respectively, for the R- patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16947712\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent and combination chemotherapy have been evaluated for the treatment of MCD. There is limited experience with hematopoietic cell transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Single agent chemotherapy",
"      </strong>",
"      ",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       Vinblastine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      have both been used as single agents, with almost all patients having symptomatic relief and a partial response [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/112\">",
"       112",
"      </a>",
"      ]. However, when single agent therapy is stopped, symptoms generally recur in two to three weeks, necessitating intermittent maintenance therapy, often lifelong [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/57,70,112\">",
"       57,70,112",
"      </a>",
"      ]. Thus, combination chemotherapy is usually preferred to monotherapy when chemotherapy is given.",
"     </li>",
"     <li>",
"      <strong>",
"       Addition of glucocorticoids",
"      </strong>",
"       When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      was given along with glucocorticoids in a small study, overall response rates approached 90 percent, with four out of nine patients treated with chlorambucil plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      reported to have achieved a complete response [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/61,62,68,71\">",
"       61,62,68,71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Four-drug combinations ",
"      </strong>",
"      Selected patients may benefit from more aggressive combination chemotherapy. In two studies, approximately 50 percent of patients achieved durable complete responses after treatment with four-drug combinations such as CHOP (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"       table 1",
"      </a>",
"      ) or CVAD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. In a report of nine patients with MCD who were treated with combination chemotherapy, five were alive with no evidence of disease and four were alive with progressive disease at a mean follow-up of about four years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hematopoietic cell transplantation",
"      </strong>",
"      &mdash; Long-term survivals were reported in three patients with MCD (one with POEMS syndrome and one with non-Hodgkin lymphoma) who were treated successfully with hematopoietic cell transplantation after failing treatment with chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/113-115\">",
"       113-115",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antiviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations in MCD correlate with the serum viral load of HHV-8, which suggests that they may be directly related to replicating virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/57\">",
"     57",
"    </a>",
"    ]. HHV-8 replication is sensitive in vitro to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    at achievable plasma concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although antiviral drugs have not proven effective against Kaposi sarcoma, which is characterized by latent HHV-8 infection, lytic HHV-8 infection is prevalent in MCD, providing a rationale for such therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Efficacy data are limited. In a pilot study, 14 HIV-infected patients with HHV-8-associated MCD were treated with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (600 mg PO every six hours) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (900 mg PO every 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/117\">",
"     117",
"    </a>",
"    ]. Major clinical and biochemical responses occurred in 12 and 7 patients, respectively. After a median follow-up of 43 months, overall survival at 12 months and beyond was 86 percent. Little clinical activity has been observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , however.",
"   </p>",
"   <p>",
"    Data are also limited on the use other antiviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      resulted in both clinical and virologic responses in three",
"      <span class=\"nowrap\">",
"       HIV+/HHV-8+",
"      </span>",
"      patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interferon alpha induced a complete response in two of three patients that lasted for three to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      produced little clinical benefit in seven treated cases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/103,119,120\">",
"       103,119,120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Inhibition of interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutralizing antibodies against interleukin (IL)-6, such as siltuximab, have demonstrated clinical efficacy in MCD, resulting in symptom resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/54,55,121\">",
"     54,55,121",
"    </a>",
"    ]. However, in some reports, the benefits were transient and symptoms recurred soon after therapy was stopped.",
"   </p>",
"   <p>",
"    An alternative approach is the use of a monoclonal antibody blocking the IL-6 receptor rather than IL-6 itself. In one study, all seven patients had resolution of clinical symptoms, followed by improvement in lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/122\">",
"     122",
"    </a>",
"    ]. However, symptoms recurred once therapy was stopped.",
"   </p>",
"   <p>",
"    A multicenter prospective open-label trial evaluated the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    (also called atlizumab or MRA), a humanized anti-human IL-6 receptor monoclonal antibody, in 28 symptomatic patients with MCD of the plasma cell type [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/123\">",
"     123",
"    </a>",
"    ]. No patient was HIV+ and only two were seropositive for HHV-8. The patients were initially treated with tocilizumab at a dose of 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every two weeks for 16 weeks, with an extension phase permitting variable dosing after this time. Major results of this study include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After 16 weeks of treatment, nutritional status and fatigue scores were significantly improved, as were lymphadenopathy and markers of inflammation, such as C-reactive protein and erythrocyte sedimentation rate.",
"     </li>",
"     <li>",
"      Mean hemoglobin levels improved from 9.2 to 12.0",
"      <span class=\"nowrap\">",
"       g/dL;",
"      </span>",
"      no patient required transfusion during this period.",
"     </li>",
"     <li>",
"      Of the 15 patients receiving treatment with corticosteroids at baseline, the average daily dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (16",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was able to be decreased by about one-half over the course of therapy.",
"     </li>",
"     <li>",
"      During the extension period, all patients remained on treatment, and the efficacy observed during the first 16 weeks was sustained or improved over the course of one year, with some subjects receiving this agent for up to three years.",
"     </li>",
"     <li>",
"      Adverse reactions were common but mild, and included symptoms related to the common cold (eg, cough, rhinorrhea, pharyngitis). Infusion-related symptoms (eg, low grade fever) were also readily manageable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    is another agent that has been shown to inhibit IL-6 levels. In highly anecdotal reports, this agent, alone or in combination with antiviral agents, has been reported to be effective in some patients with MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/124-128\">",
"     124-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these results and other anecdotal reports are encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/129-131\">",
"     129-131",
"    </a>",
"    ], it is difficult to judge the extent of the clinical, as opposed to the laboratory, improvement experienced by the patients. Furthermore, the observed efficacy may be restricted to the",
"    <span class=\"nowrap\">",
"     HIV-negative/HHV-8-negative",
"    </span>",
"    subset of patients, who probably have a disease that is different from that of HIV-infected patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    has been approved for use in MCD in Japan since 2005, but not in Europe and the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16947997\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have been frequently used as a systemic therapy. The response rate is 60 to 70 percent with zero to 20 percent being complete responses, which are usually not durable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/62,68,71\">",
"     62,68,71",
"    </a>",
"    ]. They have not been reported to have efficacy in HIV+ MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/51/6970/abstract/57,70\">",
"     57,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the main use for glucocorticoids in MCD is as part of combination chemotherapy regimens, such as CHOP and CVAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Castleman's disease (CD, angiofollicular lymph node hyperplasia) is a lymphoproliferative disorder associated with infection from the human immunodeficiency virus (HIV) and human herpesvirus 8 (HHV-8). CD comprises at least two distinct diseases (unicentric and multicentric) with very different prognoses. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.) Both conditions can be associated with development of malignancies, such as non-Hodgkin lymphoma. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Unicentric Castleman&rsquo;s disease",
"      </strong>",
"       Unicentric (localized) CD is most often an isolated asymptomatic lymphoproliferative disorder of young adults. The vast majority of lesions are in the mediastinum and lung. Peripheral lymphadenopathy is unusual and laboratory and clinical abnormalities are seen in less than 25 percent of cases. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unicentric Castleman's disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete resection of the involved node should be performed whenever possible, rather than simple biopsy or incomplete resection. Such treatment is universally curative, with no relapses reported to date. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the involved node cannot be completely removed because of its anatomic location, localized radiation therapy can be employed, but is curative in less than 50 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Multicentric Castleman&rsquo;s disease",
"      </strong>",
"       Patients with multicentric Castleman's disease (MCD) present at a median age between 52 and 65 with fever, night sweats, weight loss, and weakness or fatigue. Peripheral lymphadenopathy is nearly universal, generalized, and often accompanied by hepatosplenomegaly. Laboratory abnormalities include anemia, hypoalbuminemia, hypergammaglobulinemia, and an elevated sedimentation rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The prognosis of untreated MCD is poor. Median survival was 26 to 30 months and 8 to 14 months in the pre- and post-HIV eras, respectively. (See",
"      <a class=\"local\" href=\"#H16947063\">",
"       'Disease progression and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Almost all treatments using single agents (eg, anti-viral, anti-cytokine, chemotherapy, corticosteroids) are palliative, with disease recurrence once they are stopped. (See",
"      <a class=\"local\" href=\"#H21405924\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most symptomatic patients without evidence for organ failure, we suggest the use of the monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      over single agent therapy or combination chemotherapy such as CHOP or CVAD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Such treatment has resulted in two-year overall and relapse-free survival rates of 94 to 95 percent and 79 to 85 percent, respectively. (See",
"      <a class=\"local\" href=\"#H148951866\">",
"       'Rituximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21405924\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients with evidence of organ failure or poor performance status, we suggest the addition of a chemotherapeutic agent to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Experience is greatest with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenously for four weeks, although several case reports have described success with CHOP without rituximab. CHOP with rituximab has not yet been studied in MCD.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/1\">",
"      CASTLEMAN B, IVERSON L, MENENDEZ VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/2\">",
"      Flendrig JA, Schillings PHM. Benign giant lymphoma: The clinical signs and symptoms. Folia Med Neerl 1969; 12:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/3\">",
"      Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/4\">",
"      Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/5\">",
"      Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993; 20:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/6\">",
"      Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/7\">",
"      Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/8\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/9\">",
"      Dupin N, Gorin I, Deleuze J, et al. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med 1995; 333:798; author reply 798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/10\">",
"      Yamasaki S, Iino T, Nakamura M, et al. Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease. Br J Haematol 2003; 120:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/11\">",
"      Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 2011; 16:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/12\">",
"      Roca B. Castleman's Disease. A Review. AIDS Rev 2009; 11:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/13\">",
"      Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/14\">",
"      Schulte KM, Talat N. Castleman's disease--a two compartment model of HHV8 infection. Nat Rev Clin Oncol 2010; 7:533.",
"     </a>",
"    </li>",
"    <li>",
"     Frizzera G. Atypical lymphoproliferative disorders. In: Neoplastic Hematopathology, Knowles DM (Ed), Lippincott, Williams and Wilkins, Philadelphia 2001. p.595.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/16\">",
"      Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001; 97:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/17\">",
"      Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/18\">",
"      Dargent JL, Lespagnard L, Sirtaine N, et al. Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman's disease and featuring a follicular growth pattern. APMIS 2007; 115:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/19\">",
"      Soulier J, Grollet L, Oksenhendler E, et al. Molecular analysis of clonality in Castleman's disease. Blood 1995; 86:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/20\">",
"      Radaszkiewicz T, Hansmann ML, Lennert K. Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant. Histopathology 1989; 14:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/21\">",
"      Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. Am J Clin Pathol 1994; 101:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/22\">",
"      Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol 1996; 105:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/23\">",
"      Hanson CA, Frizzera G, Patton DF, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. Am J Pathol 1988; 131:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/24\">",
"      Hall PA, Donaghy M, Cotter FE, et al. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology 1989; 14:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/25\">",
"      Kikuta H, Itakura O, Taneichi K, Kohno M. Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease. Br J Haematol 1997; 99:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/26\">",
"      Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/27\">",
"      Cesarman E, Knowles DM. Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Semin Diagn Pathol 1997; 14:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/28\">",
"      Gessain A, Bri&egrave;re J, Angelin-Duclos C, et al. Human herpes virus 8 (Kaposi's sarcoma herpes virus) and malignant lymphoproliferations in France: a molecular study of 250 cases including two AIDS-associated body cavity based lymphomas. Leukemia 1997; 11:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/29\">",
"      Luppi M, Barozzi P, Maiorana A, et al. Human herpesvirus-8 DNA sequences in human immunodeficiency virus-negative angioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity. Blood 1996; 87:3903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/30\">",
"      Matsushima AY, Strauchen JA, Lee G, et al. Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus. Am J Surg Pathol 1999; 23:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/31\">",
"      Du MQ, Diss TC, Liu H, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002; 100:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/32\">",
"      Gessain A, Sudaka A, Bri&egrave;re J, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 1996; 87:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/33\">",
"      Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 2001; 51:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/34\">",
"      Chadburn A, Cesarman E, Nador RG, et al. Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer 1997; 80:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/35\">",
"      Hernandez JL, Gomez-Roman J, Ramos-Estebanez C, et al. Human herpesvirus 8 and Epstein-Barr virus coinfection in localized Castleman disease during pregnancy. Haematologica 2005; 90 Suppl:ECR 35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/36\">",
"      Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999; 96:4546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/37\">",
"      Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/38\">",
"      Staskus KA, Sun R, Miller G, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol 1999; 73:4181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/39\">",
"      Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 2011; 121:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/40\">",
"      Judde JG, Lacoste V, Bri&egrave;re J, et al. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 2000; 92:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/41\">",
"      Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/42\">",
"      Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. Blood 1991; 78:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/43\">",
"      Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/44\">",
"      Cannon JS, Nicholas J, Orenstein JM, et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis 1999; 180:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/45\">",
"      Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/46\">",
"      Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93:4034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/47\">",
"      Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998; 91:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/48\">",
"      Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 2012; 119:5173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/49\">",
"      Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004; 199:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/50\">",
"      An J, Lichtenstein AK, Brent G, Rettig MB. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood 2002; 99:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/51\">",
"      An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 2003; 22:3371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/52\">",
"      Keller SA, Hernandez-Hopkins D, Vider J, et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006; 107:3295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/53\">",
"      Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999; 104:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/54\">",
"      Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/55\">",
"      Foussat A, Fior R, Girard T, et al. Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman's disease. AIDS 1999; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/56\">",
"      Kawabata H, Tomosugi N, Kanda J, et al. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 2007; 92:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/57\">",
"      Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/58\">",
"      Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 1997; 175:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/59\">",
"      Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg 2012; 255:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/60\">",
"      Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/61\">",
"      Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/62\">",
"      Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/63\">",
"      Estephan FF, Elghetany MT, Berry M, Jones DV Jr. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease. Cancer Invest 2005; 23:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/64\">",
"      Maslovsky I, Uriev L, Lugassy G. The heterogeneity of Castleman disease: report of five cases and review of the literature. Am J Med Sci 2000; 320:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/65\">",
"      Larroche C, Cacoub P, Soulier J, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 2002; 69:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/66\">",
"      Kop EN, MacKenzie MA. Clinical images: Castleman disease and paraneoplastic pemphigus. CMAJ 2010; 182:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/67\">",
"      Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009; 20:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/68\">",
"      Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/69\">",
"      Kessler E. Multicentric giant lymph node hyperplasia. A report of seven cases. Cancer 1985; 56:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/70\">",
"      Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/71\">",
"      Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985; 16:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/72\">",
"      Bower M, Newsom-Davis T, Naresh K, et al. Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease. J Clin Oncol 2011; 29:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/73\">",
"      Dossier A, Meignin V, Fieschi C, et al. Human Herpesvirus 8-Related Castleman Disease in the Absence of HIV Infection. Clin Infect Dis 2013; 56:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/74\">",
"      Guihot A, Couderc LJ, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur Respir J 2005; 26:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/75\">",
"      Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood 2011; 118:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/76\">",
"      Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/77\">",
"      Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 2010; 116:4415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/78\">",
"      Guihot A, Couderc LJ, Rivaud E, et al. Thoracic radiographic and CT findings of multicentric Castleman disease in HIV-infected patients. J Thorac Imaging 2007; 22:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/79\">",
"      Ulbright TM, Santa Cruz DJ. Kaposi's sarcoma: relationship with hematologic, lymphoid, and thymic neoplasia. Cancer 1981; 47:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/80\">",
"      Rywlin AM, Rosen L, Cabello B. Coexistence of Castleman's disease and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol 1983; 5:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/81\">",
"      Chen KT. Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol 1984; 8:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/82\">",
"      Zietz C, Bogner JR, Goebel FD, L&ouml;hrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999; 340:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/83\">",
"      Colleoni GW, Duarte LC, Kerbauy FR, et al. 2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. Acta Oncol 2003; 42:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/84\">",
"      Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002; 99:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/85\">",
"      Abdel-Reheim FA, Koss W, Rappaport ES, Arber DA. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Arch Pathol Lab Med 1996; 120:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/86\">",
"      Drut R, Larregina A. Angiofollicular lymph node transformation in Hodgkin's lymphoma. Pediatr Pathol 1991; 11:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/87\">",
"      Maheswaran PR, Ramsay AD, Norton AJ, Roche WR. Hodgkin's disease presenting with the histological features of Castleman's disease. Histopathology 1991; 18:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/88\">",
"      McAloon EJ. Hodgkin's disease in a patient with Castleman's disease. N Engl J Med 1985; 313:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/89\">",
"      Molini&eacute; V, Diebold J, P&eacute;ri&eacute; G. Hodgkin's disease associated with localized or multicentric Castleman's disease. Arch Pathol Lab Med 1995; 119:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/90\">",
"      Saletti P, Ghielmini M, Scali G, et al. Hodgkin's and Castleman's disease in a patient with systemic mastocytosis. Ann Hematol 1999; 78:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/91\">",
"      Zarate-Osorno A, Medeiros LJ, Danon AD, Neiman RS. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med 1994; 118:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/92\">",
"      B&eacute;lec L, Authier FJ, Mohamed AS, et al. Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman's disease. Clin Infect Dis 1999; 28:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/93\">",
"      B&eacute;lec L, Mohamed AS, Authier FJ, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 1999; 93:3643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/94\">",
"      Kim DE, Kim HJ, Kim YA, Lee KW. Kaposi's sarcoma herpesvirus-associated Castleman's disease with POEMS syndrome. Muscle Nerve 2000; 23:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/95\">",
"      Zumo L, Grewal RP. Castleman's disease-associated neuropathy: no evidence of human herpesvirus type 8 infection. J Neurol Sci 2002; 195:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/96\">",
"      Gherardi RK, B&eacute;lec L, Fromont G, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood 1994; 83:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/97\">",
"      Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 1994; 97:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/98\">",
"      Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998; 157:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/99\">",
"      Mian H, Leber B. Mixed variant multicentric Castleman disease treated with rituximab: case report. J Pediatr Hematol Oncol 2010; 32:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/100\">",
"      Hoffmann C, Schmid H, M&uuml;ller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011; 118:3499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/101\">",
"      G&eacute;rard L, B&eacute;rezn&eacute; A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/102\">",
"      Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 2004; 45:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/103\">",
"      Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98:3473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/104\">",
"      Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/105\">",
"      Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006; 76:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/106\">",
"      Bestawros A, Michel R, S&eacute;guin C, Routy JP. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol 2008; 83:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/107\">",
"      Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman's disease. Am J Hematol 2008; 83:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/108\">",
"      Ramasamy K, Gandhi S, Tenant-Flowers M, et al. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012; 158:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/109\">",
"      Casquero A, Barroso A, Fern&aacute;ndez Guerrero ML, G&oacute;rgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol 2006; 85:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/110\">",
"      Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 2009; 113:4521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/111\">",
"      G&eacute;rard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012; 119:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/112\">",
"      Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001; 66:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/113\">",
"      Repetto L, Jaiprakash MP, Selby PJ, et al. Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol 1986; 4:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/114\">",
"      Advani R, Warnke R, Rosenberg S. Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Ann Oncol 1999; 10:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/115\">",
"      Ganti AK, Pipinos I, Culcea E, et al. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol 2005; 79:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/116\">",
"      Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/117\">",
"      Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011; 117:6977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/118\">",
"      Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/119\">",
"      Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/120\">",
"      Senanayake S, Kelly J, Lloyd A, et al. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003; 71:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/121\">",
"      van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/122\">",
"      Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/123\">",
"      Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/124\">",
"      Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006; 134:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/125\">",
"      Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009; 2:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/126\">",
"      Sobas MA, Alonso Vence N, Diaz Arias J, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 2010; 89:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/127\">",
"      Wang X, Ye S, Xiong C, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. Jpn J Clin Oncol 2011; 41:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/128\">",
"      Sbenghe MM, Besa E, Mahipal A, et al. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. Oncologist 2012; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/129\">",
"      Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007; 46:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/130\">",
"      Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol 2009; 90:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/51/6970/abstract/131\">",
"      Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116:3627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4707 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.38",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Queens Family Health Team",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-178.173.136.2-E371FC2C7B-S317699.S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6970=[""].join("\n");
var outline_f6_51_6970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Human herpesvirus 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UNICENTRIC CASTLEMAN'S DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MULTICENTRIC CASTLEMAN'S DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1997782\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16947056\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4258355\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16947063\">",
"      Disease progression and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21405924\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148951866\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5347459\">",
"      Use in HIV+ patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16947712\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Inhibition of interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16947997\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4707\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4707|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"RADIOL_87767\" title=\"diagnostic image 1\">",
"      Multicentric Castlemans disease imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4707|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/54/876\" title=\"table 1\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=related_link\">",
"      Virology, epidemiology, and transmission of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_51_6971="Sonohysterography indications and contraindications";
var content_f6_51_6971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications and contraindications to saline infusion sonohysterography",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal uterine bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine cavity abnormalities that are suspected or noted on transvaginal sonography&nbsp;(eg, leiomyomas, polyps, synechiae)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital abnormalities of the uterine cavity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infertility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent pregnancy loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic infection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6971=[""].join("\n");
var outline_f6_51_6971=null;
var title_f6_51_6972="Empiric treatment psoas abscess";
var content_f6_51_6972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antiobitic therapy for psoas abscess in adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Empiric therapy with activity against methicillin-resistant S. aureus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preferred",
"      </td>",
"      <td>",
"       Vancomycin (30 mg/kg IV every 24 h in 2 equally divided doses)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Alternatives",
"      </td>",
"      <td>",
"       Daptomycin (6 mg/kg IV once daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Linezolid (600 mg IV or orally twice daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       PLUS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Empiric therapy with activity against gram-negative and anaerobic pathogens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"2\">",
"       Ampicillin-sulbactam (3 g every 6 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"2\">",
"       Piperacillin/tazobactam (3.375 g every 6 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"2\">",
"       Ticarcillin-clavulanate (3.1 g every 4 to 6 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       A third generation cephalosporin such as ceftriaxone (1 g IV every 24 hours)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole (500 mg IV every 8 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole (500 mg IV every 8 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Monotherapy with a carbapenem&bull; such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"2\">",
"       Imipenem (500 mg every 6 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"2\">",
"       Meropenem (1 g every 8 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"2\">",
"       Ertapenem (1 g daily)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antibiotic therapy should be tailored to culture and sensitivity data when available.",
"     <br>",
"      &bull; Carbapenems should not be used for patients with history of immediate-type hypersensitivity to beta-lactams.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6972=[""].join("\n");
var outline_f6_51_6972=null;
var title_f6_51_6973="Physical findings in obese children";
var content_f6_51_6973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Findings of note on physical examination in children with obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Exam finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical concern raised",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Short stature",
"        </p>",
"        OR unexplained decrease in height velocity",
"       </td>",
"       <td>",
"        <p>",
"         Height &lt;50th percentile with weight &gt;95th percentile* (if not explained by familial short stature)",
"        </p>",
"        Growth velocity &lt;5 cm/year in a prepubertal child, or declining across over two or more height percentile curves on a standard chart (eg, decreasing from the 90th to the 50th percentile)",
"       </td>",
"       <td>",
"        Endocrine or genetic condition (eg, Cushing syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        Hypertension if systolic or diastolic blood pressure &gt;95th percentile for age, gender, and height on &ge;3 occasions",
"       </td>",
"       <td>",
"        Essential hypertension, renal disease, or Cushing syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acanthosis nigricans",
"       </td>",
"       <td>",
"        Hyperpigmented, thickened, velvety skin in body folds and creases, particularly neck",
"       </td>",
"       <td>",
"        Increased risk of insulin resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive acne, hirsutism",
"       </td>",
"       <td>",
"        Hirsutism: excessive growth of hair in atypical areas, such as face and neck",
"       </td>",
"       <td>",
"        Polycystic ovary syndrome (PCOS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Violaceous striae",
"       </td>",
"       <td>",
"        Linear lesions, red, pink, or purple in color, particularly on abdomen",
"       </td>",
"       <td>",
"        Cushing syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papilledema, cranial nerve VI paralysis",
"       </td>",
"       <td>",
"        Optic disc swelling on funduscopic exam, caused by increased intracranial pressure",
"       </td>",
"       <td>",
"        Pseudotumor cerebri (idiopathic intracranial hypertension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tonsillar hypertrophy",
"       </td>",
"       <td>",
"        Tonsils occupy more than 50 percent of the lateral dimension of oropharynx",
"       </td>",
"       <td>",
"        Obstructive sleep apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goiter",
"       </td>",
"       <td>",
"        Enlarged or swollen thyroid gland",
"       </td>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheezing",
"       </td>",
"       <td>",
"        High-pitched whistling on auscultation",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly, right upper quadrant tenderness",
"       </td>",
"       <td>",
"        Increased liver span",
"       </td>",
"       <td>",
"        Non-alcoholic fatty liver disease, or gallstones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micropenis",
"       </td>",
"       <td>",
"        Unusually small penis",
"       </td>",
"       <td>",
"        In most cases the small-appearing penis is actually normal size; the length is buried under suprapubic fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undescended testes",
"       </td>",
"       <td>",
"        Testicle not palpable in scrotum",
"       </td>",
"       <td>",
"        Prader-Willi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal gait, limp, pain in hip or groin, limited range of motion in hip",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Slipped capital femoral epiphysis (SCFE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowing of tibia",
"       </td>",
"       <td>",
"        Lower leg angles inward, causing a bowleg appearance",
"       </td>",
"       <td>",
"        Blount disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small hands and feet, or polydactyly",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Genetic condition (eg, Prader-Willi syndrome or Bardet-Biedl syndrome)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most children with obesity who have not completed linear growth are relatively tall for their age. Therefore, height &lt;50th percentile is unusual.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6973=[""].join("\n");
var outline_f6_51_6973=null;
var title_f6_51_6974="Contents: Pediatric resuscitation";
var content_f6_51_6974=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric resuscitation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric resuscitation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28948\">",
"           Assessment of perfusion in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29030\">",
"           Basic airway management in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7864\">",
"           Basic life support in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44328\">",
"           Carbon dioxide monitoring (capnography)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/24/27014\">",
"           Continuous oxygen delivery systems for infants, children, and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/48/29450\">",
"           Emergent endotracheal intubation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20746\">",
"           Guidelines for pediatric advanced life support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/59/41912\">",
"           Hypovolemic shock in children: Initial evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22327\">",
"           Initial assessment and stabilization of children with respiratory or circulatory compromise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14104\">",
"           Initial evaluation of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/8/26762\">",
"           Initial management of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42901\">",
"           Physiology and classification of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15738\">",
"           Primary drugs in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24026\">",
"           Rapid sequence intubation (RSI) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13354\">",
"           Septic shock: Ongoing management after resuscitation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4634\">",
"           Septic shock: Rapid recognition and initial resuscitation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10346\">",
"           Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15481\">",
"           The difficult pediatric airway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8057\">",
"           Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-1A2581AFBA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_51_6974=[""].join("\n");
var outline_f6_51_6974=null;
var title_f6_51_6975="Striae in Cushings disease";
var content_f6_51_6975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Striae in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axillary and lower abdominal striae in a 21-year-old man with Cushing's disease. Abdominal obesity is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David N Orth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_51_6975=[""].join("\n");
var outline_f6_51_6975=null;
